heart failure

Post hoc analysis of SCORED trial sheds positive light on Inpefa for heart failure
Post hoc analysis of SCORED trial sheds positive light on Inpefa for heart failure
Clinical Trials Arena
Lexicon Pharmaceuticals
Inpefa
clinical trials
heart failure
AHA
Flag link:
Corteria Pharmaceuticals raises €65M in series A funding to address heart failure
Corteria Pharmaceuticals raises €65M in series A funding to address heart failure
Finsmes
Corteria
funding
heart failure
Flag link:
BioCardia’s Cell Therapy Unlikely to Meet Primary Endpoint in Phase III Heart Failure
BioCardia’s Cell Therapy Unlikely to Meet Primary Endpoint in Phase III Heart Failure
BioSpace
BioCardia
clinical trials
cell therapy
heart failure
CardiAMP
Flag link:
Bayer looks to expand Kerendia label to include heart failure
Bayer looks to expand Kerendia label to include heart failure
Clinical Trials Arena
Bayer
Kerendia
clinical trials
heart failure
Flag link:
On a roll, Novo's star obesity drug Wegovy shows benefits in patients with heart failure
On a roll, Novo's star obesity drug Wegovy shows benefits in patients with heart failure
Fierce Pharma
Novo Nordisk
Wegovy
heart failure
clinical trials
Flag link:
Lexicon's Inpefa safe and effective for HF, large-scale trial shows
Lexicon's Inpefa safe and effective for HF, large-scale trial shows
Clinical Trials Arena
Lexicon
clinical trials
heart failure
Inpefa
Flag link:
Biocardia takes a pause for thought
Biocardia takes a pause for thought
EP Vantage
BioCardia
CardiAMP
stem cell therapy
heart failure
Flag link:
Lexicon gets FDA approval for Inpefa to treat heart failure
Lexicon gets FDA approval for Inpefa to treat heart failure
Pharmaceutical Technology
Lexicon Pharmaceuticals
FDA
Inpefa
heart failure
Flag link:
Farxiga’s approval for expanded use highlights potential to differentiate in HF space
Farxiga’s approval for expanded use highlights potential to differentiate in HF space
Clinical Trials Arena
AstraZeneca
Farxiga
heart failure
Flag link:
Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications
Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Jardiance
heart failure
Flag link:
FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv
FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv
Fierce Pharma
Cytokinetics
heart failure
FDA
complete response letter
Omecamtiv Mecarbil
Flag link:
Novo sows the seeds for a new heart failure approach
Novo sows the seeds for a new heart failure approach
EP Vantage
Novo Nordisk
HS-001
cell therapy
heart failure
Flag link:
Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy
Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy
Pharmaphorum
Novo Nordisk
Heartseed
clinical trials
HS-001
cell therapy
heart failure
Flag link:
AstraZeneca's Forxiga nabs expanded heart failure approval in Europe
AstraZeneca's Forxiga nabs expanded heart failure approval in Europe
Fierce Pharma
AstraZeneca
Europe
Forxiga
heart failure
Flag link:
FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use
FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use
Fierce Biotech
FDA
Cytokinetics
heart failure
Omecamtiv Mecarbil
Flag link:
Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics' potential heart drug
Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics' potential heart drug
Endpoints
FDA
Cytokinetics
heart failure
Omecamtiv Mecarbil
Flag link:
Abbott’s HeartMate 3 extends life by 5 years for advanced heart failure patients
Abbott’s HeartMate 3 extends life by 5 years for advanced heart failure patients
MedCity News
Abbott Labs
Medtech
devices
HeartMate 3
advanced heart failure
heart failure
Flag link:
Bayer’s BlueRock inks cardiovascular cell therapy delivery deal
Bayer’s BlueRock inks cardiovascular cell therapy delivery deal
Fierce Pharma
Bayer
BlueRock Therapeutics
heart failure
cell therapy
BioCardia
Flag link:
Abbott Gets to the Heart of Extending Life-Expectancy with HeartMate 3 Data
Abbott Gets to the Heart of Extending Life-Expectancy with HeartMate 3 Data
Medical Devices and Diagnostics Industry
Abbott Labs
devices
Medtech
heart failure
HeartMate 3
Flag link:
AstraZeneca’s Farxiga reduces CV mortality risk in Phase III trials
AstraZeneca’s Farxiga reduces CV mortality risk in Phase III trials
Clinical Trials Arena
AstraZeneca
Farxiga
clinical trials
heart failure
Flag link:

Pages